A second aspect of growing interest are safety concerns regarding CAA patients in need for either acute ischemic stroke treatment with intravenous recombinant tissue plasminogen activator (rtPA) or long-term treatment with platelet aggregation inhibitors and/or oral anticoagulants (Reuter et al., 2014; Charidimou et al., 2015a; Wilson et al., 2015). The gene discussed is PLAT; the disease is ischemic stroke.